RT Journal Article
SR Electronic
T1 An ergonomic assessment tool for evaluating the effect of back exoskeletons on injury risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.22.21260715
DO 10.1101/2021.07.22.21260715
A1 Karl E. Zelik
A1 Cameron A. Nurse
A1 Mark C. Schall, Jr
A1 Richard F. Sesek
A1 Matthew C. Marino
A1 Sean Gallagher
YR 2021
UL http://medrxiv.org/content/early/2021/10/20/2021.07.22.21260715.abstract
AB Low back disorders (LBDs) are a leading injury in the workplace. Back exoskeletons (exos) are wearable assist devices that complement traditional ergonomic controls and reduce LBD risks by alleviating musculoskeletal overexertion. However, there are currently no ergonomic assessment tools to evaluate risk for workers wearing back exos. Exo-LiFFT, an extension of the Lifting Fatigue Failure Tool, is introduced as a means to unify the etiology of LBDs with the biomechanical function of exos. We present multiple examples demonstrating how Exo-LiFFT can assess or predict the effect of exos on LBD risk without costly, time-consuming electromyography studies. For instance, using simulated and real-world material handling data we show an exo providing a 30 Nm lumbar moment is projected to reduce cumulative back damage by ∼70% and LBD risk by ∼20%. Exo-LiFFT provides a practical, efficient ergonomic assessment tool to assist safety professionals exploring back exos as part of a comprehensive occupational health program.HIGHLIGHTSBack exos are wearable assist devices that complement ergonomic controls for reducing low back disorder (LBD) risksHowever, no ergonomic assessment tools exist to evaluate LBD risks for workers wearing back exosWe introduce Exo-LiFFT, an ergonomic assessment tool adapted from the Lifting Fatigue Failure ToolExo-LiFFT is a practical tool that unifies the etiology of LBDs and biomechanical function of exosExo-LiFFT can be used to assess or predict the effect of exos on LBD risk without EMG testingCompeting Interest StatementAuthors K.E.Z. and M.C.M. have a financial interest in HeroWear, LLC, which manufactures and sells occupational exos.Funding StatementThe study was partially supported by the NIH (R01EB028105), and by the Deep South Center for Occupational Health and Safety, a NIOSH Education and Research Center (5 T42 OH 008436-16). The contents are solely the responsibility of the authors and do not represent official views of the Deep South Center, NIOSH, or NIH. These funding sources were not involved in study design, in the collection, analysis or interpretation of data, or in the decision to submit this article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human subjects data were collected. This manuscript includes simulation results and analysis of public data (NIH Exemption 4).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author, K.E.Z., upon reasonable request.